Quanterix Corp (NASDAQ:QTRX) – Analysts at Leerink Swann issued their FY2017 EPS estimates for Quanterix in a note issued to investors on Tuesday. Leerink Swann analyst P. Souda anticipates that the company will post earnings per share of ($1.17) for the year. Leerink Swann currently has a “Outperform” rating and a $27.00 target price on the stock. Leerink Swann also issued estimates for Quanterix’s Q4 2017 earnings at ($0.29) EPS, Q1 2018 earnings at ($0.23) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.22) EPS, FY2018 earnings at ($0.90) EPS, Q1 2019 earnings at ($0.17) EPS, Q2 2019 earnings at ($0.10) EPS, Q3 2019 earnings at ($0.05) EPS, Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.30) EPS and FY2020 earnings at $0.37 EPS.
Several other brokerages have also issued reports on QTRX. BTIG Research assumed coverage on shares of Quanterix in a research note on Tuesday. They issued a “buy” rating and a $26.00 target price on the stock. Cowen assumed coverage on shares of Quanterix in a research note on Tuesday. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Quanterix in a research report on Tuesday. They issued an “overweight” rating on the stock.
In other news, major shareholder Venture Fund Viii Overage Arch purchased 266,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $3,990,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David R. Walt purchased 200,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was purchased at an average price of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 500,000 shares of company stock worth $7,500,000 over the last quarter.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which is a developer of tools in high definition diagnostics. The Company offers single molecule array (Simoa) platform, whcich uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.